Today we gathered to celebrate Dr. Thiemann's retirement from his career as an interventional cardiologist! Thank you for all your years of service and dedication. We wish you the best on your next chapter!🧑‍⚕️🩺🫀🎉

Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT | JACC: Advances jacc.org/doi/10.1016/j.…

Open it. Zoom it. Save it. Share it. This is your go-to guide for standard adult TTE views.

Troponin In dialysis patients, is it low/high/the same? Another study from our group. With SABOURETCardiologist mdpi.com/2077-0383/14/1… PCRonline 🫀 @Sbrugaletta Luis Ortega Paz @Anazmicalik @guilbom Prof. Hector M. Garcia-Garcia Nicola Ryan Pascal Meier,MD @W_jyg Ignacio Cigalini 🇦🇷 Hany Ragy SABOURETCardiologist

I'm thrilled to share that we've successfully completed randomization of 1,104 patients with severe coronary artery disease in the #P4 trial, comparing CT-guided PCI vs. IVUS-guided PCI. This marks a major milestone in one of the most ambitious trials in interventional

Device embolisation after left atrial appendage closure (LAAC) occurs in approximately 0.1% of cases—rare, yet memorable. Effective management requires familiarity with several critical aspects. This paper summarises the European Left Atrial Appendage Closure Club consensus

MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (Luca Valenti), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and

In this randomised trial of ACS patients with non-culprit lesions, intensive lipid-lowering therapy led to significant plaque lipid regression within 12 weeks. However, adding PCSK9 inhibition offered no further short-term benefit, and plaque volume and physiology remained

Join me at my late breaking science session European Society of Cardiology where i will be presenting SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction esc365.escardio.org/ESC-Congress/s… And hopefully a simultaneous publication in European Heart Journal

Some pills from the #PIpELINe trial... the exercise 🏃‍♀️ training 💪mixed few supervised sessions and 🏡 based exercises. The compliance was around 75%. 🔝as compared to previous studies

It was a please to present our late break science, a post hoc analysis of SURMOUNT-5 RCT. A packed out auditorium- with simultaneous publication in European Society of Cardiology Journals , although i cant find link 🤣 Please read Hany Ragy thread beliw for the slides presented European Society of Cardiology Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

Mitral Clip in a patient with LVAD. With Mony Shuvy 💪 PCRonline 🫀 @Sbrugaletta Luis Ortega Paz @Anazmicalik @guilbom Prof. Hector M. Garcia-Garcia Nicola Ryan Pascal Meier,MD @W_jyg Ignacio Cigalini 🇦🇷 Hany Ragy SABOURETCardiologist Mamas A. Mamas David J. Cohen, MD, MSc Gregg W. Stone MD James Torey PA-C EAPCIPresident C. Michael Gibson MD Elliot Smith

Poor sleep health is associated with older brain age: the role of systemic inflammation - eBioMedicine thelancet.com/journals/ebiom…

We authored this state-of-the-art review, now published in JACC, to provide an updated, comprehensive overview of post–myocardial infarction inflammatory mechanisms and to critically evaluate the emerging clinical evidence on anti-inflammatory therapies for secondary

🔬 New finding: High Lipoprotein(a) is linked with elevated arachidonic acid levels. Read more 👉 ow.ly/uIF950XcOJz #CardioResearch #LipoproteinA #Lipidology

🔍 Large-bore vascular closure: ProGlide or MANTA? A new patient-level meta-analysis of randomized trials by Oliver Dumpies et al. compares outcomes between these two commonly used devices. ➡️ Result: ProGlide was associated with fewer vascular and bleeding complications than the

The DOSE Trial: In a multicenter RCT (n=1,001), operator radiation exposure was compared between left distal radial vs right transradial access at left wrist, head, and chest. No significant differences. jacc.org/doi/10.1016/j.… #TCT2025 #JACCINT

Results of the SELUTION DE NOVO trial - comparing Selution (𝗖𝗼𝗿𝗱𝗶𝘀) DEB strategy to routine stenting in de novo CAD - shows non-inferiority of the device against a primary endpoint of target vessel failure at one year #TCT2025

SELUTION DeNovo met its primary endpoint of noninferiority at 1 year, with “only” 20% of DES required as bailout in the drug-coated balloon arm. Imaging use was limited in both groups, while specialty balloons were more frequently employed in the DCB+DES arm (though not

Whoaaaaa!!!Cutting balloon as good as IVL.. #TCT2025 @CRF